AFFY
Affymax, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mar. 19, 2013, 3:05 PM

    It's a bad day for Affymax (AFFY), with the stock plunging 64% and hitting a new year low after announcing late Monday that it's slashing 75% of its workforce and considering filing for bankruptcy protection. The company is hiring a bank to look at strategic options, including a possible sale, a restructuring, or a winding down, but many are concerned that it may be too little, too late.

    | Mar. 19, 2013, 3:05 PM | 2 Comments
  • Jul. 2, 2012, 2:38 PM
    Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax.
    | Jul. 2, 2012, 2:38 PM